Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Guggenheim Cuts Price Target on Tetraphase Pharma (TTPH) Following Disappointing cUTI Data.
September 9, 2015 7:57 AM EDTGuggenheim reiterated a Buy rating on Tetraphase Pharmaceuticals (NASDAQ: TTPH), and cut the price target to $20.00 (from $60.00), on disappointing cUTI data.
Analyst Louise Chen commented, "Despite disappointing cUTI data, we are maintaining our BUY rating for TTPH shares, but we are lowering our price target from $60 to $20. The decrease in our PT is driven by downwards earnings revisions and multiple contraction. In... More
